You can now read 10 articles each month for free on BostonGlobe.com.

The Boston Globe

Business

Mass. Movers

Analysts raise price target on Insulet

A diabetic tests his blood-sugar level.

Associated Press/File 2009

A diabetic tests his blood-sugar level.

Continue reading below

Canaccord Genuity analysts set a $37 price target on Insulet Corp. stock, dailypolitical.com reported. The firm currently rates the stock a “buy.” “Management has positively commented . . . that new patient growth remains robust,” analysts wrote. In the most recent quarter, revenue rose 20 percent, compared to the same quarter last year. Bedford-based Insulet makes the OmniPod Insulin Management System for people with insulin-dependent diabetes.

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week